… and development of AMN107 is discussed, as is the current status of AMN107 in clinical …
of mechanisms of resistance to AMN107, and how and where AMN107 is expected to fit into the …

… AMN107 is a new higher-potency inhibitor of BCR-ABL. To identify mutations in BCR-ABL
that could result in resistance to AMN107, a cDNA library of BCR-ABL mutants was introduced …

… Having characterized nilotinib (AMN107) against a large panel of imatinib mesylate–resistant
Bcr-Abl mutants, we investigated which mutants might arise under nilotinib therapy using a …

… Nilotinib (Tasigna [nilotinib], formerly known as AMN107; … the Bcr-Abl tyrosine kinase than
imatinib. Like imatinib, it acts through competitive inhibition of the ATP binding site of BCR-ABL…

… Nilotinib was effective in patients harboring BCR-ABL … resistance mechanism independent
of BCR-ABL mutations. Adverse … In summary, nilotinib is highly active and safe in patients with …

… , nilotinib … of nilotinib was also demonstrated in 32/33 Im-resistant mutant cell lines. We
sought to investigate the efficacy of nilotinib in vivo according to the type of preexisting BCR-ABL …

… Although the AMN107-sensitive cell lines DOHH-… AMN107-resistant T-cell lines. In conclusion,
this is the first report providing evidence that activity of AMN107 is not restricted to Bcr-Abl, …

… Methods: We evaluated the efficacy of nilotinib as first line therapy … (BCR-ABL/ABL ratio
≤0.05% in our lab) at 12 months (mo). Results: Thirty-two pts have been treated with nilotinib …

Nilotinib is a novel, highly selective oral Bcr-Abl inhibitor which is approximately 30-fold more
potent than imatinib. High response rates with nilotinib were observed in all CML phases …

… AMN107 (nilotinib) are potent alternate Abl inhibitors with activity against many imatinib
mesylate–resistant BCR-ABL … )–exposed Ba/F3-p210 BCR-ABL cells to compare incidence and …